Schematic diagram of study design and completion of vaccination schedule.

<p>The CONSORT diagram indicates the number of subjects screened to complete enrollment of 40 subjects in a factorial study design. Subjects were stratified by pre-existing Ad5 neutralizing antibody reciprocal titer of ≤500 or >500 then randomized to receive DNA priming by Biojector® or needle and syringe (N/S). In addition, 50% of each subgroup was boosted with rAd5 at 10¹⁰ PU and the other 50% received 10¹¹ PU.